melphalan

Summary

Summary: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.

Top Publications

  1. Kuznetsova N, Sevrin C, Lespineux D, Bovin N, Vodovozova E, Meszaros T, et al. Hemocompatibility of liposomes loaded with lipophilic prodrugs of methotrexate and melphalan in the lipid bilayer. J Control Release. 2012;160:394-400 pubmed publisher
    ..PC) and phosphatidylinositol (PI), 8:1 (mol) were loaded with 10 mol% of either methotrexate or melphalan 1,2-dioleoylglyceride esters (MTX-DOG and Mlph-DOG respectively) and either decorated with 2 mol% of sialyl ..
  2. Molina B, Alonso L, Gonzalez Vicent M, Andion M, Hernandez C, Lassaletta A, et al. High-dose busulfan and melphalan as conditioning regimen for autologous peripheral blood progenitor cell transplantation in high-risk neuroblastoma patients. Pediatr Hematol Oncol. 2011;28:115-23 pubmed publisher
    ..The conditioning regimen used in all cases consisted of high-dose of busulfan and melphalan. Median age at transplantation was 3 years (range: 0.7-14 years)...
  3. de Lima V, de Carvalho A, Morato Marques M, Hashimoto V, Spilborghs G, Marques S, et al. TNF-alpha and melphalan modulate a specific group of early expressed genes in a murine melanoma model. Cytokine. 2013;62:217-25 pubmed publisher
    Cutaneous melanoma displays high morbidity and mortality rates. Isolated limb perfusion with melphalan (Mel) is used for the treatment of non-resectable, locally advanced extremity melanomas...
  4. Grabellus F, Stylianou E, Umutlu L, Sheu S, Lehmann N, Taeger G, et al. Size-based clinical response evaluation is insufficient to assess clinical response of sarcomas treated with isolated limb perfusion with TNF-? and melphalan. Ann Surg Oncol. 2012;19:3375-85 pubmed publisher
    ..For nonresectable sarcomas, hyperthermic isolated limb perfusion with TNF-? and melphalan (TM-ILP) yields high response rates...
  5. Nieto Y, Thall P, Valdez B, Andersson B, Popat U, Anderlini P, et al. High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies. Biol Blood Marrow Transplant. 2012;18:1677-86 pubmed publisher
    We developed a new high-dose combination of infusional gemcitabine with busulfan and melphalan for lymphoid tumors...
  6. Ghassemi F, Shields C. Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma. Arch Ophthalmol. 2012;130:1268-71 pubmed publisher
    ..To evaluate the efficacy and complications of intravitreal chemotherapy for viable vitreous seeding from retinoblastoma...
  7. Marr B, Brodie S, Dunkel I, Gobin Y, Abramson D. Three-drug intra-arterial chemotherapy using simultaneous carboplatin, topotecan and melphalan for intraocular retinoblastoma: preliminary results. Br J Ophthalmol. 2012;96:1300-3 pubmed
    To report outcomes with selective intra-arterial chemotherapy (SIAC) using simultaneous carboplatin, topotecan, and melphalan for advanced intraocular retinoblastoma.
  8. Lamottke B, Kaiser M, Mieth M, Heider U, Gao Z, Nikolova Z, et al. The novel, orally bioavailable HSP90 inhibitor NVP-HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases. Eur J Haematol. 2012;88:406-15 pubmed publisher
    ..Exposure of MM cells to a combination of NVP-HSP990 and either melphalan or histone deacetylase (HDAC) inhibitors caused synergistic inhibition of viability, increased induction of ..
  9. Huismans A, Kroon H, Haydu L, Kam P, Thompson J. Is melphalan dose adjustment according to ideal body weight useful in isolated limb infusion for melanoma?. Ann Surg Oncol. 2012;19:3050-6 pubmed publisher
    ..Adjusting melphalan dose according to ideal body weight (IBW) has been proposed as a method of decreasing limb toxicity without ..

More Information

Publications75

  1. Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci M, Catalano J, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366:1759-69 pubmed publisher
    ..This double-blind, multicenter, randomized study compared melphalan-prednisone-lenalidomide induction followed by lenalidomide maintenance (MPR-R) with melphalan-prednisone-..
  2. Beasley G, Riboh J, Augustine C, Zager J, Hochwald S, Grobmyer S, et al. Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma. J Clin Oncol. 2011;29:1210-5 pubmed publisher
    Isolated limb infusion (ILI) with melphalan (M-ILI) dosing corrected for ideal body weight (IBW) is a well-tolerated treatment for patients with in-transit melanoma with a 29% complete response rate...
  3. Delforge M, Terpos E, Richardson P, Shpilberg O, Khuageva N, Schlag R, et al. Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma. Eur J Haematol. 2011;86:372-84 pubmed publisher
    ..This post hoc analysis of the phase III VISTA trial of bortezomib plus melphalan-prednisone (VMP) vs...
  4. Gieling R, Parker C, De Costa L, Robertson N, Harris A, Stratford I, et al. Inhibition of carbonic anhydrase activity modifies the toxicity of doxorubicin and melphalan in tumour cells in vitro. J Enzyme Inhib Med Chem. 2013;28:360-9 pubmed publisher
    ..g. melphalan), but limiting access of weak bases (e.g. doxorubicin)...
  5. Morabito F, Gentile M, Mazzone C, Rossi D, Di Raimondo F, Bringhen S, et al. Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment. Blood. 2011;118:5759-66 pubmed publisher
    ..safety, and reversal of renal impairment (RI) in untreated patients with multiple myeloma given bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide (VMPT-VT) maintenance or bortezomib-melphalan-..
  6. Dimopoulos M, Delforge M, Hajek R, Kropff M, Petrucci M, Lewis P, et al. Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial. Haematologica. 2013;98:784-8 pubmed publisher
    ..diagnosed multiple myeloma aged 65 years or over were randomized 1:1:1 to nine 4-week cycles of lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance; or lenalidomide, melphalan, and prednisone, or melphalan ..
  7. Sousa M, Zub K, Aas P, Hanssen Bauer A, Demirovic A, Sarno A, et al. An inverse switch in DNA base excision and strand break repair contributes to melphalan resistance in multiple myeloma cells. PLoS ONE. 2013;8:e55493 pubmed publisher
    ..the levels of proteins mediating DNA damage signaling and -repair in RPMI8226 multiple myeloma cells and its Melphalan-resistant derivative 8226-LR5...
  8. Boegsted M, Holst J, Fogd K, Falgreen S, Sørensen S, Schmitz A, et al. Generation of a predictive melphalan resistance index by drug screen of B-cell cancer cell lines. PLoS ONE. 2011;6:e19322 pubmed publisher
    ..MM) a range of new drugs have been introduced and now challenge conventional therapy including high dose melphalan. Consequently, the generation of predictive signatures for response to melphalan may have a clinical impact...
  9. Kato K, Yoshida N, Matsumoto K, Matsuyama T. Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia. Pediatr Blood Cancer. 2014;61:712-6 pubmed publisher
    ..a "non-BU, non-TBI conditioning regimen," which consisted of fludarabine (FLU), cytarabine (CA), and melphalan (L-PAM) after FLAG combined with L-PAM...
  10. Grabellus F, Kraft C, Sheu Grabellus S, Bauer S, Podleska L, Lauenstein T, et al. Tumor vascularization and histopathologic regression of soft tissue sarcomas treated with isolated limb perfusion with TNF-? and melphalan. J Surg Oncol. 2011;103:371-9 pubmed publisher
    ..Some tumors show an insufficient association between radiological and pathological response. We investigated STS after TM-ILP with a primary emphasis on histologic regression patterns...
  11. Waśko Grabowska A, Rzepecki P, Oborska S, Barzał J, Gawronski K, Młot B, et al. Efficiency of supersaturated calcium phosphate mouth rinse treatment in patients receiving high-dose melphalan or BEAM prior to autologous blood stem cell transplantation: a single-center experience. Transplant Proc. 2011;43:3111-3 pubmed publisher
    ..We tested the ability of supersaturated calcium phosphate mouth rinse (Caphosol) to ameliorate oral mucosal injury induced by a conditioning regimen...
  12. Deroose J, van Geel A, Burger J, Eggermont A, Verhoef C. Isolated limb perfusion with TNF-alpha and melphalan for distal parts of the limb in soft tissue sarcoma patients. J Surg Oncol. 2012;105:563-9 pubmed publisher
    ..Tumor necrosis factor-alpha (TNF) and melphalan-based isolated limb perfusion (TM-ILP) is effective in locally advanced STS of the extremities...
  13. Visani G, Malerba L, Stefani P, Capria S, Galieni P, Gaudio F, et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood. 2011;118:3419-25 pubmed publisher
    ..180 mg/m², and 200 mg/m² given on days -7 and -6) coupled with fixed doses of etoposide, cytarabine, and melphalan (BeEAM regimen) as the conditioning regimen to autologous stem cell transplantation for resistant/relapsed ..
  14. Offidani M, Polloni C, Cavallo F, Liberati A, Ballanti S, Pulini S, et al. Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma. Leuk Lymphoma. 2012;53:1722-7 pubmed publisher
    The combination of melphalan, prednisone and thalidomide (MPT) has demonstrated efficacy and acceptable toxicity in newly diagnosed and relapsed/refractory patients with multiple myeloma (MM)...
  15. Hjorth M, Hjertner Ø, Knudsen L, Gulbrandsen N, Holmberg E, Pedersen P, et al. Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study. Eur J Haematol. 2012;88:485-96 pubmed publisher
    ..been frequently used for second-line therapy in patients with myeloma relapsing after or refractory to initial melphalan-based treatment, but no randomized trials have been published comparing these two treatment alternatives...
  16. Casanova F, Quarti J, da Costa D, Ramos C, da Silva J, Fialho E. Resveratrol chemosensitizes breast cancer cells to melphalan by cell cycle arrest. J Cell Biochem. 2012;113:2586-96 pubmed publisher
    b>Melphalan (MEL) is a chemotherapeutic agent used in breast cancer therapy; however, MEL's side effects limit its clinical applications...
  17. Schaiquevich P, Buitrago E, Taich P, Torbidoni A, Ceciliano A, Fandino A, et al. Pharmacokinetic analysis of melphalan after superselective ophthalmic artery infusion in preclinical models and retinoblastoma patients. Invest Ophthalmol Vis Sci. 2012;53:4205-12 pubmed publisher
    To characterize melphalan pharmacokinetics after superselective ophthalmic artery infusion (SSOAI) in animals and children with retinoblastoma.
  18. San Miguel J, Schlag R, Khuageva N, Dimopoulos M, Shpilberg O, Kropff M, et al. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol. 2013;31:448-55 pubmed publisher
    ..analysis of the phase III VISTA trial (Velcade As Initial Standard Therapy in Multiple Myeloma: Assessment With Melphalan and Prednisone) was conducted to determine whether the overall survival (OS) benefit with bortezomib-melphalan-..
  19. Blijlevens N, de Château M, Krivan G, Rabitsch W, Szomor A, Pytlik R, et al. In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient's burden. Bone Marrow Transplant. 2013;48:966-71 pubmed publisher
    This randomized-controlled trial studied the efficacy of palifermin in a chemotherapy-only, high-dose Melphalan (HDM) transplant setting, to reduce oral mucositis (OM) and its sequelae measured by patient-reported outcomes (PRO) and ..
  20. Tsimpida M, Thompson D, Liasis A, Smith V, Kingston J, Sagoo M, et al. Visual outcomes following intraophthalmic artery melphalan for patients with refractory retinoblastoma and age appropriate vision. Br J Ophthalmol. 2013;97:1464-70 pubmed publisher
    To determine the frequency and cause of visual loss following intra-arterial melphalan (IAM) in patients with retinoblastoma with age appropriate vision.
  21. Cibeira M, Sanchorawala V, Seldin D, Quillen K, Berk J, Dember L, et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood. 2011;118:4346-52 pubmed publisher
    Previous studies have suggested that, in patients with AL amyloidosis treated with high-dose melphalan and autologous stem-cell transplantation (HDM/SCT), the greatest benefit is seen in those patients achieving a hematologic complete ..
  22. Rellick S, Piktel D, Walton C, Hall B, Petros W, Fortney J, et al. Melphalan exposure induces an interleukin-6 deficit in bone marrow stromal cells and osteoblasts. Cytokine. 2012;58:245-52 pubmed publisher
    ..In the current study we demonstrate that exposure of BMSC or HOB to melphalan leads to decreases in IL-6 protein expression...
  23. Delioukina M, Zain J, Palmer J, Tsai N, Thomas S, Forman S. Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine-melphalan conditioning for treatment of mature T-cell lymphomas. Bone Marrow Transplant. 2012;47:65-72 pubmed publisher
    ..haematopoietic cell transplantation at the City of Hope, Duarte, CA, USA, using a reduced-intensity fludarabine/melphalan conditioning regimen between the years 2001 and 2008...
  24. Fayers P, Palumbo A, Hulin C, Waage A, Wijermans P, Beksac M, et al. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood. 2011;118:1239-47 pubmed publisher
    ..Six randomized controlled trials, launched in or after 2000, compared melphalan and prednisone alone (MP) and with thalidomide (MPT). The effect on overall survival (OS) varied across trials...
  25. Osher D, Kushner Y, Arseneau J, Foulkes W. Melphalan as a treatment for BRCA-related ovarian carcinoma: can you teach an old drug new tricks?. J Clin Pathol. 2011;64:924-6 pubmed publisher
    ..The patient was subsequently treated with oral melphalan therapy and has not recurred in over 25 years...
  26. Deroose J, Eggermont A, van Geel A, Burger J, Den Bakker M, de Wilt J, et al. Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas. J Clin Oncol. 2011;29:4036-44 pubmed publisher
    ..resectable or facilitate function-preserving surgery can be achieved by tumor necrosis factor ? (TNF) -based and melphalan-based isolated limb perfusion (TM-ILP)...
  27. Raymond A, Beasley G, Broadwater G, Augustine C, Padussis J, Turley R, et al. Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution. J Am Coll Surg. 2011;213:306-16 pubmed publisher
    ..Using a prospectively maintained database, we reviewed our experience with melphalan-based HILP (which included 62 first-time and 10 second-time) and ILI (which included 126 first-time and 18 ..
  28. Shields C, Manjandavida F, Arepalli S, Kaliki S, Lally S, Shields J. Intravitreal melphalan for persistent or recurrent retinoblastoma vitreous seeds: preliminary results. JAMA Ophthalmol. 2014;132:319-25 pubmed publisher
    ..To describe the technique and evaluate the efficacy and complications of intravitreal melphalan for vitreous seeding from retinoblastoma...
  29. Landau H, Hassoun H, Rosenzweig M, Maurer M, Liu J, Flombaum C, et al. Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis. Leukemia. 2013;27:823-8 pubmed publisher
    To improve the efficacy of risk-adapted melphalan (MEL) in patients with amyloidosis (AL), we conducted a phase II trial using bortezomib and dexamethasone (BD) as consolidation...
  30. Madan S, Kumar S, Dispenzieri A, Lacy M, Hayman S, Buadi F, et al. High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement. Blood. 2012;119:1117-22 pubmed publisher
    High-dose melphalan (HDM) plus stem cell transplantation is an effective treatment for light-chain amyloidosis (AL), but is associated with high treatment-related mortality in patients with cardiac involvement...
  31. Muen W, Kingston J, Robertson F, Brew S, Sagoo M, Reddy M. Efficacy and complications of super-selective intra-ophthalmic artery melphalan for the treatment of refractory retinoblastoma. Ophthalmology. 2012;119:611-6 pubmed publisher
    To report the efficacy of super-selective intra-ophthalmic artery melphalan (IAM) for the treatment of refractory retinoblastoma and any associated complications of this treatment.
  32. Verelst S, Termorshuizen F, Uyl de Groot C, Schaafsma M, Ammerlaan A, Wittebol S, et al. Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial. Ann Hematol. 2011;90:1427-39 pubmed publisher
    Thalidomide with melphalan/prednisone (MPT) was defined as standard treatment in elderly patients with multiple myeloma (MM) based on five randomized trials...
  33. Li J, Zhang W, Jiao L, Duan M, Guan H, Zhu W, et al. Combination of melphalan and dexamethasone for patients with newly diagnosed POEMS syndrome. Blood. 2011;117:6445-9 pubmed publisher
    ..Based on the efficacy and low toxicity of a combination of melphalan and dexamethasone (MDex) for light chain amyloidosis, we conducted a prospective study of MDex treatment for ..
  34. Suzuki S, Yamane T, Mohri M, Kaneko A. Selective ophthalmic arterial injection therapy for intraocular retinoblastoma: the long-term prognosis. Ophthalmology. 2011;118:2081-7 pubmed publisher
    ..To report the success rate, adverse events, and long-term prognosis of selective ophthalmic arterial injection (SOAI) therapy for intraocular retinoblastoma...
  35. Abidi M, Agarwal R, Ayash L, Deol A, Al Kadhimi Z, Abrams J, et al. Melphalan 180 mg/m2 can be safely administered as conditioning regimen before an autologous stem cell transplantation (ASCT) in multiple myeloma patients with creatinine clearance 60 mL/min/1.73 m2 or lower with use of palifermin for cytoprotection: . Biol Blood Marrow Transplant. 2012;18:1455-61 pubmed publisher
    High-dose melphalan 140 mg/m2 is the standard of care for patients with multiple myeloma (MM) with renal insufficiency (RI)...
  36. Brodie S, Munier F, Francis J, Marr B, Gobin Y, Abramson D. Persistence of retinal function after intravitreal melphalan injection for retinoblastoma. Doc Ophthalmol. 2013;126:79-84 pubmed publisher
    The risk/benefit profile of intravitreal melphalan injection for treatment of active vitreous seeds in retinoblastoma remains uncertain...
  37. Abidi M, Agarwal R, Tageja N, Ayash L, Deol A, Al Kadhimi Z, et al. A phase I dose-escalation trial of high-dose melphalan with palifermin for cytoprotection followed by autologous stem cell transplantation for patients with multiple myeloma with normal renal function. Biol Blood Marrow Transplant. 2013;19:56-61 pubmed publisher
    b>Melphalan 200 mg/m(2) is the standard conditioning regimen for patients with multiple myeloma (MM) with normal renal function (NRF) undergoing autologous stem cell transplant (ASCT)...
  38. Papadia F, Basso V, Patuzzo R, Maurichi A, Di Florio A, Zardi L, et al. Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma. J Surg Oncol. 2013;107:173-9 pubmed publisher
    ..This exploratory trial evaluates safety and clinical activity of L19-TNF plus melphalan-containing isolated limb perfusion (ILP) in extremity melanoma patients...
  39. Zhang H, Chen J, Zeng Z, Que W. Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity. J Int Med Res. 2013;41:584-95 pubmed publisher
  40. Berenson J, Boccia R, Siegel D, Bozdech M, Bessudo A, Stadtmauer E, et al. Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study. Br J Haematol. 2006;135:174-83 pubmed
    We assessed the safety and efficacy of melphalan, arsenic trioxide (ATO) and ascorbic acid (AA) (MAC) combination therapy for patients with multiple myeloma (MM) who failed more than two different prior regimens...
  41. Beksac M, Haznedar R, Firatli Tuglular T, Ozdogu H, Aydogdu I, Konuk N, et al. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. Eur J Haematol. 2011;86:16-22 pubmed publisher
    The combination of melphalan-prednisone-thalidomide (MPT) has been investigated in several clinical studies that differed significantly with regard to patient characteristics and treatment schedules...
  42. Moreno Ramirez D, de la Cruz Merino L, Ferrandiz L, Villegas Portero R, Nieto Garcia A. Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety. Oncologist. 2010;15:416-27 pubmed publisher
    ..were conducted to identify studies fulfilling the following inclusion criteria: hyper- or normothermic ILP with melphalan with or without tumor necrosis factor (TNF) or other drugs providing valid data on clinical response, survival, ..
  43. Luksch R, Grignani G, Fagioli F, Brach del Prever A, Podda M, Aliberti S, et al. Response to melphalan in up-front investigational window therapy for patients with metastatic Ewing's family tumours. Eur J Cancer. 2007;43:885-90 pubmed
    The aim of the study was to determine the activity and toxicity of melphalan as a single agent given in up-front therapy for patients with newly-diagnosed Ewing's family tumours with bone/bone marrow metastases...
  44. van Ginkel R, Thijssens K, Pras E, van der Graaf W, Suurmeijer A, Hoekstra H. Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: three time periods at risk for amputation. Ann Surg Oncol. 2007;14:1499-506 pubmed
    ..limb salvage rate and overall survival after isolated limb perfusion (ILP) with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma (STS)...
  45. Foguem C, Kantelip B, Deconinck E, Hafsaoui C, Meaux Ruault N, Gil H, et al. [Kappa light chain deposition disease, presenting as Sjögren's syndrome, successfully treated by high-dose melphalan and autologous blood stem transplantation]. Rev Med Interne. 2009;30:49-52 pubmed publisher
    ..as sicca syndrome with salivary glands hypertrophy and polyneuropathy successfully treated by high dose melphalan and autologous blood stem transplantation...
  46. Gonçalves T, Benvegnú D, Bonfanti G, Frediani A, Rocha J. delta-Aminolevulinate dehydratase activity and oxidative stress during melphalan and cyclophosphamide-BCNU-etoposide (CBV) conditioning regimens in autologous bone marrow transplantation patients. Pharmacol Res. 2009;59:279-84 pubmed publisher
    ..We have also compared common drugs that are used during CR, namely, melphalan (M-200) and cyclophosphamide-BCNU-etoposide (CBV), in order to determine whether either of them could be less ..
  47. Katoh N, Matsuda M, Yoshida T, Yazaki M, Morita H, Sakashita K, et al. Primary AL amyloid polyneuropathy successfully treated with high-dose melphalan followed by autologous stem cell transplantation. Muscle Nerve. 2010;41:138-43 pubmed publisher
    ..associated with amyloid derived from light chains (AL) who were treated successfully with high-dose melphalan followed by autologous peripheral blood stem cell transplantation (HDM/SCT)...
  48. Hayes A, Neuhaus S, Clark M, Thomas J. Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma. Ann Surg Oncol. 2007;14:230-8 pubmed
    Isolated limb perfusion (ILP) with melphalan is used in the treatment of advanced in-transit melanoma but has no real efficacy for irresectable soft tissue sarcomas arising in the extremities...
  49. Kaiser M, Lamottke B, Mieth M, Jensen M, Quadt C, Garcia Echeverria C, et al. Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma. Eur J Haematol. 2010;84:337-44 pubmed publisher
    ..of the combination partners histone deacetylase inhibitor NVP-LBH589, suberoylanilide hydroxamic acid (SAHA), melphalan, or doxorubicin, either simultaneously or in sequential patterns...
  50. Van Besien K, Kunavakkam R, Rondon G, de Lima M, Artz A, Oran B, et al. Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes. Biol Blood Marrow Transplant. 2009;15:610-7 pubmed publisher
    ..We compared the outcome of 95 patients treated at the University of Chicago with fludarabine melphalan (Flu + Mel) + alemtuzumab conditioning and 59 patients treated at the M.D...
  51. van Iersel L, Verlaan M, Vahrmeijer A, van Persijn van Meerten E, Tijl F, Sparidans R, et al. Hepatic artery infusion of high-dose melphalan at reduced flow during isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: a clinical and pharmacologic evaluation. Eur J Surg Oncol. 2007;33:874-81 pubmed
    ..To increase local drug exposure, we administered melphalan at a reduced flow in the hepatic artery during IHP (hepatic artery infusion, hepatic artery-portal vein ..
  52. Cavo M, Di Raimondo F, Zamagni E, Patriarca F, Tacchetti P, Casulli A, et al. Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. J Clin Oncol. 2009;27:5001-7 pubmed publisher
    ..In comparison with double ASCT, the addition of first-line thalidomide to double ASCT improved clinical outcomes. Short-term thalidomide was generally well tolerated and had no adverse impact on postrelapse survival. ..
  53. Berenson J, Yang H, Vescio R, Nassir Y, Mapes R, Lee S, et al. Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up. Ann Hematol. 2008;87:623-31 pubmed publisher
    Bortezomib synergizes with melphalan in preclinical and early clinical studies...
  54. Kroon H, Lin D, Kam P, Thompson J. Efficacy of repeat isolated limb infusion with melphalan and actinomycin D for recurrent melanoma. Cancer. 2009;115:1932-40 pubmed publisher
    ..In all patients, a cytotoxic combination of melphalan and actinomycin D was used. : The median time between the 2 procedures was 11 months...
  55. Seldin D, Anderson J, Skinner M, Malek K, Wright D, Quillen K, et al. Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65. Blood. 2006;108:3945-7 pubmed
    Recently, protocols using high-dose melphalan chemotherapy and autologous peripheral blood stem cell transplantation (HDM/SCT) have been developed for the treatment of patients with immunoglobulin light chain (AL) amyloidosis...
  56. Trudel S, Stewart A, Li Z, Shu Y, Liang S, Trieu Y, et al. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan. Clin Cancer Res. 2007;13:621-9 pubmed
    ..ABT-737 showed a synergistic effect when combined with dexamethasone or melphalan in inducing myeloma cell death...
  57. Sonneveld P, van der Holt B, Segeren C, Vellenga E, Croockewit A, Verhoe G, et al. Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial. Haematologica. 2007;92:928-35 pubmed
    ..MM were randomized after VAD induction chemotherapy to receive two cycles of non-myeloablative intermediate-dose melphalan (70 mg/m2) (single treatment) or the same regimen followed by cyclophosphamide 120 mg/kg iv plus total body ..
  58. Vogl D, Liu S, Chong E, Luger S, Porter D, Schuster S, et al. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support. Am J Hematol. 2007;82:1071-5 pubmed
    High-dose melphalan with autologous stem cell support improves survival as part of initial therapy for myeloma...
  59. Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med. 2007;357:1083-93 pubmed
    ..We conducted a randomized trial comparing high-dose intravenous melphalan followed by autologous hematopoietic stem-cell rescue with standard-dose melphalan plus high-dose dexamethasone ..
  60. Kadota R, Mahoney D, Doyle J, Duerst R, Friedman H, Holmes E, et al. Dose intensive melphalan and cyclophosphamide with autologous hematopoietic stem cells for recurrent medulloblastoma or germinoma. Pediatr Blood Cancer. 2008;51:675-8 pubmed publisher
    ..To determine the response, toxicity, and survival for children with progressive or recurrent medulloblastoma and germinoma using a single myeloablative course of chemotherapy supported by autologous hematopoietic stem cells...
  61. Brodie S, Pierre Gobin Y, Dunkel I, Kim J, Abramson D. Persistence of retinal function after selective ophthalmic artery chemotherapy infusion for retinoblastoma. Doc Ophthalmol. 2009;119:13-22 pubmed publisher
    ..To assess potential retinal viability by electroretinography following selective ophthalmic artery chemotherapy infusion for retinoblastoma...
  62. Shnitsar V, Eckardt R, Gupta S, Grottker J, Müller G, Koepsell H, et al. Expression of human organic cation transporter 3 in kidney carcinoma cell lines increases chemosensitivity to melphalan, irinotecan, and vincristine. Cancer Res. 2009;69:1494-501 pubmed publisher
    ..into hOCT3 stably transfected Chinese hamster ovary (CHO) cells was inhibited by irinotecan, vincristine, and melphalan. The K(i) values [determined from Dixon plots] for irinotecan, vincristine, and melphalan were 1.72 +/- 0...
  63. Palumbo A, Bringhen S, Rossi D, Cavalli M, Larocca A, Ria R, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol. 2010;28:5101-9 pubmed publisher
    The combination of bortezomib-melphalan-prednisone (VMP) is a new standard of care for newly diagnosed multiple myeloma...
  64. Grootenboers M, Hendriks J, van Boven W, Knibbe C, van Putte B, Stockman B, et al. Pharmacokinetics of isolated lung perfusion with melphalan for resectable pulmonary metastases, a phase I and extension trial. J Surg Oncol. 2007;96:583-9 pubmed
    Isolated lung perfusion (ILuP) with melphalan was performed under normo- and hyperthermic conditions combined with pulmonary metastasectomy for patients with resectable lung metastases...
  65. Taeger G, Grabellus F, Podleska L, Muller S, Ruchholtz S. Effectiveness of regional chemotherapy with TNF-alpha/melphalan in advanced soft tissue sarcoma of the extremities. Int J Hyperthermia. 2008;24:193-203 pubmed publisher
    Hyperthermic isolated limb perfusion with tumour necrosis factor alpha (TNF-alpha) and melphalan was repeatedly reported to achieve extraordinarily high clinical remission rates in advanced and non-resectable soft tissue sarcoma of the ..
  66. Hu Y, Kirito K, Yoshida K, Mitsumori T, Nakajima K, Nozaki Y, et al. Inhibition of hypoxia-inducible factor-1 function enhances the sensitivity of multiple myeloma cells to melphalan. Mol Cancer Ther. 2009;8:2329-38 pubmed publisher
    ..by echinomycin, a specific HIF-1 inhibitor, or a siRNA against HIF-1alpha resulted in enhanced sensitivity to melphalan in myeloma cells...